Phase II study of avelumab in multiple relapsed/refractory germ cell cancer

Conclusions This study failed to achieve its primary endpoint. Our data suggest a lack of avelumab efficacy in unselected multiple relapsed/refractory GCTs.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research